

Meeting Minutes
North Dakota Medicaid Drug Use Review (DUR) Board
Meeting Date: December 4th, 2024
Time and Location: 1:00 pm CST in Bismarck, North Dakota

Call to Order:

A regular quarterly meeting of the North Dakota Medicaid Drug Use Review (DUR) Board meeting was convened at 1:04 pm CST with K. Martian presiding as Presiding Officer. DUR Board Coordinator, C. Stauter recording minutes.

Roll Call:

Board Members Voting:

Present: Stephanie Antony, Gabriela Balf, Amanda Dahl, Kurt Datz, Andrea Honeyman, Laura Kroetsch, Kevin Martian, Kristen Peterson, Amy Werremeyer, Jessica Ziegler

Absent: Tanya Schmidt

Quorum Present: Yes

Board Members Non-Voting:

Absent: Kathleen Traylor

Medicaid Pharmacy Department:

Present: Jeff Hostetter, Brendan Joyce, Alexi Murphy, LeNeika Roehrich, Katie Steig

Approval of Meeting Minutes:

Motion: Moved by K. Datz to approve the minutes of the September 4th, 2024 meeting, motion was seconded by A. Werremeyer. **Motion carried.**

The minutes of the September 4th, 2024 meeting were approved as distributed.

Reports:

Administrative Report: provided by A. Murphy

A. Murphy introduced new pharmacist K. Steig and new member J. Ziegler was introduced by K. Steig. A. Murphy discussed DUR board member vacant positions and upcoming governor and legislative changes.

Financial Report: Budget provided by B. Joyce

B. Joyce shared with the Board trends of reimbursement amount vs net spend for pharmacy drug claims. This information can be found in the handout.

Financial Report: Top Drugs provided by B. Joyce

B. Joyce presented the quarterly review of the top 25 drugs based on total number and cost of claims and the top 15 therapeutic classes based on number and cost of claims. This report can be found in the handout.

Retrospective Drug Utilization Review (RDUR) Report by C. Stauter

C. Stauter reviewed the quarterly RDUR criteria that were selected for review of each month and information from a targeted mailing. This material can be found in the handout.

Clinical Report and Annual PDL Review: Prior Authorization and Criteria Updates by C. Stauter

C. Stauter presented prior authorization and criteria updates with emphasis on the following sections in the PDL: Amyloidosis, COPD/Asthma, Secondary Hyperparathyroidism, and Annual PDL Review. Testimony was provided by Arnele Mejia from Pierre Fabre Pharmaceuticals

on Hemangeol, Jasmine Inman from Teva on Austedo, and Sunny Hirpara from Astrazeneca on Airsupra.

Unfinished business: provided by C. Stauter

C. Stauter provided updates on alternative RDUR communication tools. The presented material can be found in the handout.

New business:

Second Reviews presented by C. Stauter

C. Stauter presented group prior authorization criteria for attention-deficit hyperactivity disorder stimulants

Motion: Moved by K. Martian to place attention-deficit hyperactivity disorder stimulants on prior authorization, motion was seconded by K. Datz. **Motion carried.**

First Reviews presented by C. Stauter and J McKee

C. Stauter presented an overview of migraine prophylaxis and treatment and NSAIDs. J. McKee presented an overview of primary biliary cholangitis. The presented material can be found in the handout. Testimony was provided by Jasmine Inman from Teva on Ajovy, Craig Fjeldheim from Abbvie on Qulipta, and Porscha Showers from Gilead on Livdelzi.

Motion: Moved by A. Werremeyer to draft prior authorization for migraine prophylaxis and treatment, motion was seconded by A. Honeyman. **Motion carried.**

Motion: Moved by A. Werremeyer to draft prior authorization for NSAIDs, motion was seconded by A. Dahl. **Motion carried.**

Motion: Moved by K. Martian to draft prior authorization primary biliary cholangitis, motion was seconded by K. Datz. **Motion carried.**

Retrospective Drug Utilization Review (RDUR) Criteria Recommendations:

RDUR criteria recommendations were reviewed. The presented material can be found in the handout.

Motion: Moved by K. Peterson to approve the RDUR criteria, motion was seconded by S. Antony. **Motion carried.**

Announcements:

Next meeting is March 5th, 2025.

Adjournment:

Meeting adjourned by K. Martian at 2:13 pm CST.

Date of Minutes Approval: March 5th, 2025

Minutes submitted by: Julie McKee, Acentra Health